Gene-Directed Enzyme/Prodrug Therapy of Rat Brain Tumor Mediated by Human Mesenchymal Stem Cell Suicide Gene Extracellular Vesicles In Vitro and In Vivo.

curative effect gene-directed enzyme prodrug therapy intranasal application mesenchymal stem cells rat glioblastoma suicide gene extracellular vesicles yCD::UPRT-MSC-EVs

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
31 Jan 2022
Historique:
received: 26 11 2021
revised: 27 01 2022
accepted: 28 01 2022
entrez: 15 2 2022
pubmed: 16 2 2022
medline: 16 2 2022
Statut: epublish

Résumé

MSC-driven, gene-directed enzyme prodrug therapy (GDEPT) mediated by extracellular vesicles (EV) represents a new paradigm-cell-free GDEPT tumor therapy. In this study, we tested the efficacy of yeast cytosine deaminase::uracilphosphoribosyl transferase (yCD::UPRT-MSC)-exosomes, in the form of conditioned medium (CM) to inhibit the growth of C6 glioblastoma cells both in vitro and in vivo. MSCs isolated from human adipose tissue, umbilical cord, or dental pulp engineered to express the yCD::UPRT gene secreted yCD::UPRT-MSC-exosomes that in the presence of the prodrug 5-fluorocytosine (5-FC), inhibited the growth of rat C6 glioblastoma cells and human primary glioblastoma cells in vitro in a dose-dependent manner. CM from these cells injected repeatedly either intraperitoneally (i.p.) or subcutaneously (s.c.), applied intranasally (i.n.), or infused continuously by an ALZET osmotic pump, inhibited the growth of cerebral C6 glioblastomas in rats. A significant number of rats were cured when CM containing yCD::UPRT-MSC-exosomes conjugated with 5-FC was repeatedly injected i.p. or applied i.n. Cured rats were subsequently resistant to challenges with higher doses of C6 cells. Our data have shown that cell-free GDEPT tumor therapy mediated by the yCD::UPRT-MSC suicide gene EVs for high-grade glioblastomas represents a safer and more practical approach that is worthy of further investigation.

Identifiants

pubmed: 35159002
pii: cancers14030735
doi: 10.3390/cancers14030735
pmc: PMC8833758
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : VEGA Slovakia
ID : 1/0489/20
Organisme : SPP Foudation
ID : 2021

Références

Theranostics. 2021 Jan 1;11(6):2860-2875
pubmed: 33456577
Mol Cancer Ther. 2011 Aug;10(8):1327-36
pubmed: 21610170
Cell Rep. 2019 Apr 16;27(3):940-954.e6
pubmed: 30956133
Neoplasma. 2005;52(6):435-40
pubmed: 16284686
Stem Cells. 2021 Dec;39(12):1589-1600
pubmed: 34520591
Biochem Biophys Res Commun. 2012 Nov 16;428(2):292-7
pubmed: 23085230
Int J Cancer. 2019 Sep 15;145(6):1538-1546
pubmed: 30801698
Expert Opin Biol Ther. 2015 Apr;15(4):495-504
pubmed: 25539575
Viruses. 2018 Oct 13;10(10):
pubmed: 30322158
Int J Cancer. 2014 Mar 15;134(6):1458-65
pubmed: 24038033
Cancer Res. 2007 Jul 1;67(13):6304-13
pubmed: 17616689
Neoplasma. 2016;63(6):925-933
pubmed: 27565330
Mol Ther. 2015 May;23(5):812-823
pubmed: 25868399
Curr Pharm Des. 2017;23(40):6206-6214
pubmed: 28914201
J Clin Invest. 2000 May;105(9):1161-7
pubmed: 10791987
J Biomed Sci. 2016 Jan 22;23:15
pubmed: 26801910
Curr Stem Cell Res Ther. 2019;14(6):482-494
pubmed: 30819086
Stem Cells. 2017 Apr;35(4):851-858
pubmed: 28294454
Cell Adh Migr. 2007 Jul-Sep;1(3):156-8
pubmed: 19262134
Cancer Res. 1994 Mar 15;54(6):1503-6
pubmed: 8137255
Mol Ther. 2010 Jan;18(1):223-31
pubmed: 19844197
Theranostics. 2018 Feb 5;8(6):1481-1493
pubmed: 29556336
J Gene Med. 2008 Oct;10(10):1071-82
pubmed: 18671316
Cancer Lett. 2008 Nov 8;270(2):191-201
pubmed: 18502571
Cancer Res. 2002 Feb 1;62(3):773-80
pubmed: 11830532
J Hematol Oncol. 2021 Sep 3;14(1):136
pubmed: 34479611
Int J Nanomedicine. 2020 Apr 30;15:2999-3022
pubmed: 32431498
Nat Cell Biol. 2007 Jun;9(6):654-9
pubmed: 17486113
Adv Drug Deliv Rev. 2012 Jun 1;64(8):739-48
pubmed: 21740940
Mol Ther. 2014 Jan;22(1):140-8
pubmed: 24002694
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014 Sep;158(3):373-7
pubmed: 24145770
Int J Cancer. 2012 May 15;130(10):2455-63
pubmed: 21732344
Int J Cancer. 2019 Feb 15;144(4):897-908
pubmed: 30098225
Eur J Cancer. 2014 Sep;50(14):2478-88
pubmed: 25060826
Exp Neurol. 2022 Jan;347:113895
pubmed: 34653510
Methods Mol Biol. 2019;1895:75-85
pubmed: 30539530

Auteurs

Miroslav Tibensky (M)

Institute of Physiology, Faculty of Medicine, Comenius University, 81372 Bratislava, Slovakia.
Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, 84505 Bratislava, Slovakia.

Jana Jakubechova (J)

Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, 84505 Bratislava, Slovakia.
Department of Stem Cell Preparation, St. Elisabeth Cancer Institute, 84505 Bratislava, Slovakia.

Ursula Altanerova (U)

Department of Stem Cell Preparation, St. Elisabeth Cancer Institute, 84505 Bratislava, Slovakia.

Andrea Pastorakova (A)

Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, 81108 Bratislava, Slovakia.

Boris Rychly (B)

Alpha Medical, Ltd., 82606 Bratislava, Slovakia.

Ladislav Baciak (L)

Central Laboratories, Slovak University of Technology, 81237 Bratislava, Slovakia.

Boris Mravec (B)

Institute of Physiology, Faculty of Medicine, Comenius University, 81372 Bratislava, Slovakia.
Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, 84505 Bratislava, Slovakia.

Cestmir Altaner (C)

Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, 84505 Bratislava, Slovakia.
Department of Stem Cell Preparation, St. Elisabeth Cancer Institute, 84505 Bratislava, Slovakia.

Classifications MeSH